Fierce 15 winner CytomX is in line for a $200 million upfront payday and potentially billions in biobucks from partner Bristol-Myers Squibb as the Big Pharma…

A phase 3 trial of Nektar Therapeutics’ chronic pain asset NKTR-181 has met its primary endpoint. The clinical trial linked the mu-opioid to a statistically…

Array BioPharma has yanked its NDA to the U.S. regulator for its late-stage melanoma candidate binimetinib after the agency told the biotech its phase 3 Nemo…

The FDA has rejected AstraZeneca’s hyperkalemia drug ZS-9 for the second time in 12 months. The news marks a further blow for a program AstraZeneca saw giving…

President Donald Trump’s first budget has not gone down well with the medical research and regulatory communities, which have come out against his plans to cut…

The Nan Fung Group’s venture capital firm Pivotal bioVenture Partners has raised its first fund, totaling $300 million, as it looks to help early-stage life…

Seres Therapeutics has unveiled the design of a phase 2 trial it thinks could secure FDA approval for its microbiome drug.

Upstart eGenesis got off a healthy $38 million Series A round today as it looks to use cutting-edge science to “solve the shortage of organs for donation” by…

R&D